RECOMBINANT ONCOTOXIN AR209 (ANTI-P185 ^erbB-2 ) DIMINISHES HUMAN PROSTATE CARCINOMA XENOGRAFTS

This publication has 16 references indexed in Scilit:

• EGF receptor and p185^erbB‐2‐specific single‐chain antibody toxins differ in their cell‐killing activity on tumor cells expressing both receptor proteins
  International Journal of Cancer, 1995
• Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non- Hodgkin's lymphoma
  Blood, 1993
• Immunotoxin Therapy of Small-Cell Lung Cancer
  Chest, 1993
• Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin.
  Proceedings of the National Academy of Sciences, 1992
• Overexpression of the c‐erbB‐2/neu–encoded p185 protein in primary lung cancer
  Molecular Carcinogenesis, 1992
• Expression of c‐erb B‐2/neu proto‐oncogene in human prostatic cancer tissues and cell lines
  Molecular Carcinogenesis, 1992
• The prostate: An increasing medical problem
  The Prostate, 1990
• Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
  Science, 1989
• A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma.
  Journal of Clinical Oncology, 1985
• A MODEL FOR GASTRIC CANCER EPIDEMIOLOGY
  The Lancet, 1975